Metsera brings its portfolio of experimental obesity drugs, with MET-097i, a GLP-1 injectable, and MET-233i, which mimics the pancreatic hormone amylin, being the key among them. MET-233i is being ...

By Mariam Sunny and Michael Erman (Reuters) - Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up to $7.3 billion, including future payments, as it seeks to gain a ...

(Reuters) -Pfizer (PFE) said on Monday it would acquire drug developer Metsera (MTSR) in a deal valued at up to $7.3 billion, including future payments, as it seeks to gain a foothold in the ...

(Reuters) - Cybersecurity firm Netskope is now aiming for a valuation of up to $7.26 billion in its U.S. initial public offering after raising the proposed price range, it said on Tuesday, ...